Anti-Em

Quick links to important sections

Anti-Em

Method of action: Antiemetic

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Anti-Em

Quick Facts

Property Description
Active ingredient Dimenhydrinate
Form Oral tablets, Solutions
Pharmacological class Antihistamine (H₁-receptor antagonist), Antiemetic
General purpose Relief of nausea, vomiting, and vertigo
Origin Synthetic, Ethanolamine derivative

What Type of Medicine is Anti-Em (Dimenhydrinate)?

Anti-Em is a synthetic combination drug classified as a first-generation antihistamine and antiemetic agent primarily used to relieve symptoms of motion sickness and inner ear disturbances. The active ingredient, Dimenhydrinate (INN), is chemically defined as a salt compound, specifically the 8-chlorotheophylline salt of Diphenhydramine. This unique structure means Dimenhydrinate is considered a combination drug, comprising two distinct active entities: the core antihistamine and a mild stimulant component. This dual-component structure places it within the ethanolamine derivative family of antihistamines, a class known for its ability to cross the blood-brain barrier. Dimenhydrinate is characterized by its profile in managing disturbances stemming from the inner ear's balance mechanisms.


Composition, Form, and General Purpose

The medication is typically prepared as an oral tablet for simple administration, and its general purpose is to suppress symptoms of nausea, vomiting, dizziness, and vertigo. The formulation is commonly provided as oral tablets but is also available in liquid solutions for oral administration. Dimenhydrinate, due to its properties, provides relief by reducing nervous activity. As an antiemetic, Dimenhydrinate’s core action involves depressing the hyperstimulated labyrinthine function—the balance mechanism in the inner ear—and antagonizing H₁ histamine receptors in the brain's vestibular system. This mechanism makes the drug fundamentally useful for managing the physical symptoms caused by a typical use scenario such as motion sickness during travel or other equilibrium perturbations. The medication's over-the-counter (OTC) status in many regions underscores its established profile for patient self-management.

Regulatory References

  1. Dimenhydrinate Drug Information

What side effects are possible with Anti-Em?

Possible Side Effects and Safety Information

The official safety profile for Dimenhydrinate is structured around the frequency and type of documented adverse reactions, as established by government regulatory bodies. The most frequently observed effects relate to its action as a first-generation antihistamine.


Frequency-Classified Adverse Reactions

Classification Examples of Documented Effects
Very Common Drowsiness, Sedation
Common Dry mouth, Dizziness, Blurred vision, Difficulty with urination, Tachycardia
Uncommon Headache, Confusion, Excitation (paradoxical reaction), Constipation, Hypotension

System-Organ Class and Serious Reactions

The regulatory label categorizes reactions by the physiological system affected. Nervous System Disorders include drowsiness and confusion, while Gastrointestinal Disorders include dry mouth and constipation. Effects on the Renal and Urinary Disorders system primarily involve urinary retention. Serious reactions, though classified as Rare, include severe hypersensitivity reactions (anaphylaxis) and certain Blood and Lymphatic System Disorders (blood dyscrasias).

Population-Specific Safety Considerations

The official safety documents include specific notes for vulnerable groups. Older adults are noted to have an increased susceptibility to central nervous system effects, such as confusion and sedation, and a higher risk of urinary retention. Pediatric patients are specifically documented as having a higher potential for experiencing the paradoxical central nervous system excitation (restlessness or agitation).

Safety-Related Restrictions

Safety limitations explicitly address pre-existing conditions that may increase risk. Caution is required, or use may be restricted, in patients with conditions exacerbated by the drug’s anticholinergic properties, such as acute narrow-angle glaucoma and symptomatic prostatic hypertrophy. Regulatory texts also note that drowsiness is generally more pronounced at the start of treatment or following dose increase.

Overdose and Emergency Response

Overdose and When to Seek Help

Regulatory documentation describes Dimenhydrinate overdose as potentially presenting with a wide range of severe clinical manifestations that affect the central nervous and cardiovascular systems. Officially documented signs can include both Central Nervous System (CNS) stimulation, such as excitation, restlessness, and hallucinations, and severe CNS depression, potentially leading to profound sleepiness or coma.

Specific "atropine-like" anticholinergic symptoms are listed, including fixed and dilated pupils, flushing, dry skin, and urinary retention. Overdosage may escalate to life-threatening outcomes such as convulsions (seizures), respiratory depression, and cardiovascular collapse.

Immediate medical action is required for any suspected overdose. Regulatory documents mandate that patients experiencing hallucinations, seizures, breathing difficulties, or unresponsiveness must seek emergency medical attention immediately, which includes contacting a Poison Control Center. Treatment is designated as symptomatic and supportive, as official labeling states that no specific antidote is known.

Population-specific information notes that stimulation and convulsions are particularly likely in pediatric patients, while adults more commonly exhibit profound sedation and coma.

Therapeutic Uses of Anti-Em

What Anti-Em Treats: Main Uses and Benefits

The primary goal of Anti-Em is to provide targeted symptomatic relief across domains where symptoms related to physical discomfort and functional strain are common. The medication is commonly used to help manage the intensity of distressing manifestations and helps ease the overall symptom burden, contributing to improved day-to-day comfort. Anti-Em is relevant in contexts involving certain distressing symptoms.

It is applied in addressing gastrointestinal distress symptoms, such as nausea, queasiness, and the urge to vomit, and vestibular discomfort symptoms, including dizziness and vertigo. This symptomatic relief may help patients cope more steadily with difficult episodes and may help with functional stability. Anti-Em is often used when symptoms intensify and supportive relief is needed, such as managing motion sickness during travel or providing supportive relief against sickness following medical procedures.

Quick Facts: Therapeutic Benefit

  • Symptom Focus: Helps address symptom clusters that may become intense or disruptive, relevant for managing symptoms that interfere with daily comfort.
  • Condition Context: Applied in conditions associated with acute or disruptive episodes, useful in scenarios where symptoms escalate temporarily.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Anti-Em (Dimenhydrinate)

Official regulatory documents define strict criteria for the use of Anti-Em (Dimenhydrinate), distinguishing between populations that are eligible, require caution, or are strictly prohibited from using the medicine.

Contraindicated Populations (Must Not Use)

Use is contraindicated for several populations, meaning the medicine must not be used under any circumstances according to labeling. These include individuals with known hypersensitivity to dimenhydrinate, its components (diphenhydramine or 8-chlorotheophylline), or patients concurrently taking a Monoamine Oxidase Inhibitor (MAOI) or within 14 days of stopping one. Use is also contraindicated in neonates, premature infants, and nursing mothers.

Condition-Based Non-Eligibility

Anti-Em is absolutely contraindicated in patients with certain severe pre-existing conditions, such as narrow-angle glaucoma and certain conditions that cause urinary retention. Use is also prohibited in cases of severe hepatic or severe renal impairment.

Age and Restricted Use

Official labeling approves use for adults and children ge 6 years of age. Eligibility is restricted for children 2 to 6 years, requiring medical consultation for use. Older adults are eligible but must use the medicine with caution. Conditional use is also specified for patients with seizure disorders, certain cardiovascular diseases, and respiratory problems.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Dimenhydrinate is established in regulatory documents based on pharmacodynamic and pharmacokinetic effects with co-administered substances. The combination of Dimenhydrinate with Monoamine Oxidase Inhibitors (MAOIs) is classified as a formal contraindication. Use with an MAOI is prohibited, and a minimum separation of 14 days after stopping an MAOI is required.

Documented Pharmacodynamic Interactions

Co-administration with Central Nervous System (CNS) depressants, such as sedatives or opioids, may lead to an additive sedative effect. The drug also exhibits additive anticholinergic effects when used alongside other medicines with anticholinergic properties, including certain antihistamines and tricyclic antidepressants. Furthermore, the official labeling notes that concurrent use with ototoxic drugs (e.g., aminoglycoside antibiotics) may mask the early symptoms of ototoxicity, which is a functional constraint of the combination. Alcohol consumption may potentiate the sedative effects and is generally not advised.

Pharmacokinetic and Exposure Effects

The diphenhydramine component of Dimenhydrinate is an inhibitor of the CYP2D6 enzyme. This is classified as a pharmacokinetic interaction that suggests a potential for increased plasma exposure of other medicines that are primarily metabolized by CYP2D6, such as venlafaxine or metoprolol. Regulatory information also specifies that elderly patients may be more susceptible to experiencing enhanced interaction effects, particularly heightened sedation.

Mechanism of Action

Central Mechanism: Dual Receptor Blockade

The primary central mechanism relies on a dual blockade of key receptors in the brain: Histamine H₁ receptors and Muscarinic Acetylcholine receptors. This antagonism occurs within the Central Nervous System (CNS), targeting structures like the Vestibular Nuclei and the Vomiting Center. This dual inhibition reduces the overall neuronal excitability of these areas, which results in the dampening of excessive neurotransmitter signaling.

Depression of the Vestibular-Emetic Pathway

By modulating the signal flow within the Vestibular-Brainstem Axis, the drug depresses the hyperstimulated signal transmission from the inner ear's labyrinth. This physiological consequence elevates the necessary threshold required to activate the central vomiting reflex. This mechanism acts on pathways where nerve signaling is highly responsive to motion cues.

Functional Synergy and Sedation Modulation

Dimenhydrinate is a combination of the central depressive antihistamine component and a mild stimulant component, 8-Chlorotheophylline. This stimulant component acts by blocking Adenosine receptors, producing mild CNS excitation. This unique synergy influences the profile of central activity, as the stimulant effect provides functional opposition to the central depressive effects characteristic of the antihistamine component.

Dosage and Administration Information

How to Use Anti-Em (Dimenhydrinate): Administration Guidelines

The instructions for using Anti-Em are structured based on administration route, specific dose maximums, and critical timing requirements. The medicine is indicated for oral, intramuscular (IM), intravenous (IV), and rectal administration, covering dosage forms like tablets, solutions, and suppositories.


Dosing and Frequency

Instruction Area Guideline
Standard Adult Dose 50 mg to 100 mg per dose; maximum of 400 mg in a 24-hour period.
Dosing Frequency Administered on an as-needed basis at fixed intervals, typically every 4 to 6 hours.
Prophylactic Timing The initial dose is taken 30 minutes to 1 hour prior to anticipated motion exposure.

Preparation and Population-Specific Rules

Parenteral administration requires specific handling: the IV injection solution undergoes mandatory dilution and is administered slowly over at least two minutes. The parenteral solution is restricted from intra-arterial injection. For oral forms, chewable tablets are chewed or crushed before swallowing.

Pediatric dosing protocols establish distinct maximum daily limits for specific age groups (e.g., max 75 mg/24 hours for children 2–5 years). This follows age-validated protocols for standardized use. The overall protocol establishes Dimenhydrinate as a short-term, intermittent-use agent with a fixed procedural structure for administration.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Anti-Em (Dimenhydrinate)

Evidence for Use in Motion Sickness Prevention

Research has explored the use of Anti-Em through short-term, controlled trials (RCTs) and comprehensive systematic reviews to investigate the medicine's role in research exploring how symptoms change over time (nausea, dizziness, and vomiting) associated with movement and travel. Studies monitored data showing how symptoms evolved in the observed populations when the medicine was observed in use. Research describes patterns where the medicine was associated with differences in the number of participants reporting specific levels of discomfort. However, the evidence includes some variability in findings due to different comparison treatments, and long-term outcomes for repeated use are not fully established.

Evidence for Use in Postoperative Nausea and Vomiting (PONV)

The research relies on Randomized Controlled Trials (RCTs) and Meta-analyses. Studies was studied for its use in an effort to manage emetic symptoms occurring shortly after surgical procedures. The main outcomes research examined were the frequency of vomiting and the need for rescue antiemetic medication. Research highlights data showing the frequency of emetic symptoms in the group studied. However, studies have also indicated that an optimal dose for prevention is not entirely clear across all surgical contexts. Also, data for certain patient groups remain insufficient.

Evidence for Use in Vertigo and Vestibular Symptoms

The available research includes clinical trials and older observational studies investigating the medicine’s use for dizziness and functional imbalance. Studies monitored patient-reported outcomes describing perceived discomfort. Research provides insight into how patients reported their experience during periods of increased symptom activity. However, evidence for this indication is considered to have low certainty because the research relies significantly on older scientific literature, and there is a limited number of recent, high-quality RCTs.

What Is Still Uncertain About Anti-Em’s Clinical Evidence

For some conditions, like acute vomiting in children with gastroenteritis (stomach flu), studies did not consistently report a favorable pattern on the frequency or duration of vomiting episodes. This highlights a specific context where the clinical utility remains uncertain. Follow-up durations were limited, meaning that long-term effects are not fully established, and there is limited information regarding patient outcomes after extended use.

Key Studies & References

  1. Label: Dramamine original formula- dimenhydrinate tablet - DailyMed (Regulatory Document)

Frequently Asked Questions (FAQ)

Common questions about Anti-Em (FAQ)


Q: How quickly does Anti-Em start working after it is taken?

Label information suggests that for the prevention of motion sickness, the initial administration occurs 30 minutes to 1 hour before the activity begins. This timing is referenced in guidelines as the period required for the drug's preventative effect to begin.


Q: Are there any common foods or drinks that should be avoided when taking Anti-Em?

Official information states that Anti-Em may be taken by mouth with or without food. The main warning regarding consumption relates to alcoholic drinks, as alcohol is known to significantly increase the sedative effects of the medication.


Q: Is Anti-Em known to cause weight changes?

According to the official regulatory safety profiles, weight changes are not listed among the documented adverse reactions for Anti-Em.


Q: Is Anti-Em considered a Schedule drug or a controlled substance?

Regulatory analysis confirms that Anti-Em is not classified as a controlled substance under the U.S. Controlled Substances Act. The medication is widely available in many regions as an over-the-counter product.


Q: Why do official documents sometimes mention taking Anti-Em with food?

Official regulatory information states that the medication may be taken by mouth with or without food. This indicates the drug may be administered independently of meal times, as food intake does not significantly affect how the drug is absorbed.


Q: Why is Anti-Em not recommended for people with a history of certain bowel issues?

Because the medication has anticholinergic properties, it has the functional effect of slowing movement in the digestive system. Therefore, official documents advise that its use be restricted or require caution in patients with pre-existing conditions like gastrointestinal obstruction.


Q: Are there any known interactions between Anti-Em and herbal supplements like St. John's Wort?

Official warnings indicate the importance of informing a healthcare professional about all other medicines, vitamins, and herbal products currently being used. This is a general caution noted in regulatory guidance due to the potential for undocumented interactions with supplements.


Q: Is Anti-Em safe to take with common pain relievers like acetaminophen?

Official interaction information notes that caution is required when combining Anti-Em with common pain relievers like acetaminophen. This is primarily due to the potential for an increase in the sedative effects of Anti-Em.


Q: Are there specific lab tests or monitoring required while taking Anti-Em?

For regular, on-label use, no routine laboratory testing or monitoring is typically required. However, in situations of potential overdose or toxicity, regulatory guidelines indicate monitoring the patient's heart rhythm using an ECG is necessary.


Q: Is it possible to become physically dependent on Anti-Em?

Studies and official reviews have reported instances of dependence and tolerance, which primarily occurred in individuals who chronically consumed the medication in doses higher than recommended. Despite this, the medication is not classified as a federally controlled substance.


Q: Why is it described that the medicine affects the 'chemoreceptor trigger zone'?

Official documents describe the medication's action as inhibiting the nausea and vomiting reflex. It does this by depressing the sensitivity of the labyrinth apparatus, which relays stimuli to the chemoreceptor trigger zone (CTZ) and the vomiting center in the brain.


Q: What is the risk of overdose described in regulatory documents for Anti-Em?

Regulatory guidelines detail that an overdose can lead to severe symptoms including profound central nervous system depression or overstimulation, hallucinations, seizures, and severe cardiovascular complications like tachycardia. If overdose is suspected, immediate emergency medical services should be contacted.


Q: Is Anti-Em the same type of medicine as other common anti-nausea drugs?

Official product information classifies Anti-Em as a first-generation antihistamine and antiemetic agent. Its specific action works through anticholinergic effects, which means it blocks certain nerve signals in the brain and inner ear. This mechanism is different from how other common anti-nausea drug classes work.


Q: Does Anti-Em have an effect on mood or sleep?

Regulatory documents state that the medication commonly causes central nervous system effects such as drowsiness and sedation. These effects can significantly impact normal sleep patterns. Less common side effects related to mood include confusion and, in rare cases, a paradoxical reaction of excitement or restlessness.


Q: Can Anti-Em be used at the same time as cold and flu medicine?

Caution is advised because many cold and flu products contain ingredients that can interact with Anti-Em. Specifically, combining it with other antihistamines or central nervous system depressants can increase the risk of side effects like severe drowsiness and confusion. It is important that the complete list of ingredients be reviewed with a professional.


Q: Is there a concern about using Anti-Em if I have a history of heart issues?

Official warnings state that use is generally restricted or that caution is required in patients with certain cardiovascular diseases. This is due to the potential for side effects like tachycardia, which is an abnormally fast heart rate.


Q: Can I take Anti-Em if I am allergic to similar types of medicine?

According to regulatory documents, Anti-Em must not be used by anyone with a known hypersensitivity or allergy to the drug or its components. Official guidance indicates that caution is required for people allergic to chemically related derivatives.


Q: Is Anti-Em mentioned in official guidance for cancer treatment side effects?

The official regulatory label primarily lists the use of Anti-Em for the prevention and treatment of symptoms related to motion sickness. While the drug is classified as an antiemetic, it is not officially listed in the core documents as approved guidance for the side effects of cancer treatment.


Q: Do pregnant women or breastfeeding individuals use Anti-Em under any circumstances?

Official labeling states that the medication must not be used by nursing mothers. For individuals who are pregnant, consulting a healthcare professional is necessary to review the specific situation before use.


Q: Why does Anti-Em require a prescription?

In many regions, Anti-Em is widely available as an over-the-counter (OTC) medication. Where it requires a prescription, this status may apply due to specific regional drug classifications, or it may be related to certain high-strength forms of the drug.


Q: Does Anti-Em interact with anxiety or depression medications?

Official warnings state that Anti-Em can have additive sedative effects when taken with many medications used for anxiety or depression, including sedatives and tranquilizers. The drug can also interact with other medicines that are processed by a specific liver enzyme (CYP2D6), which affects certain antidepressants.


Q: Why are official sources cautious about mixing Anti-Em with certain antipsychotic drugs?

Caution is advised because many antipsychotic drugs have characteristics that overlap with Anti-Em's properties. These include both acting as Central Nervous System (CNS) depressants and having anticholinergic effects, which can significantly increase the risk of severe drowsiness and confusion when combined.


Q: Are there any warnings about taking Anti-Em before surgery?

Regulatory warnings note that the strong central nervous system depressant effects can pose risks when combined with other medicines used during surgery. Additionally, it may mask the early symptoms of inner ear damage (ototoxicity) caused by other medications used in a hospital setting.


Q: Are there specific symptoms that mean I should stop Anti-Em and seek medical attention?

The product label states that immediate emergency medical services should be contacted for severe signs of allergic reaction, such as hives, difficulty breathing, or swelling of the face. This action is also necessary for severe anticholinergic effects, including extreme confusion, hallucinations, or trouble passing urine.

How should Anti-Em be stored and disposed of?

How to Store and Dispose of Anti-Em (Dimenhydrinate)

Official regulatory labeling dictates specific conditions for storing and disposing of Anti-Em to ensure stability and public safety.


Storage Requirements

Anti-Em must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The product requires protection from moisture and must be kept in its original, tightly closed container.

Child Safety and Disposal

It is mandatory to store the medication out of the sight and reach of children.

Expired or unused Anti-Em must not be discarded in household trash or via wastewater systems (drains/toilets). Disposal should follow pharmaceutical waste protocols, typically requiring consultation with a pharmacist or local waste disposal service.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Anti-Em found in:

A-Z Index: